Amgen Will Buy Peptide Firm Kai | April 16, 2012 Issue - Vol. 90 Issue 16 | Chemical & Engineering News
Volume 90 Issue 16 | p. 8 | News of The Week
Issue Date: April 16, 2012

Amgen Will Buy Peptide Firm Kai

Biopharmaceuticals: Acquisition adds a late-stage therapeutic to the biotech’s pipeline
Department: Business
Keywords: biotechnology, biosimilars, M&A

April 2012 Sells AstraZeneca a stake in development of five Amgen drugs for $50 million.

January 2012 Acquires Micromet, developer of antibody technology, for $1.2 billion.

December 2011 Agrees to $400 million payment from Watson to co­develop biosimilars.

April 2011 Acquires Bergamo, a Brazilian drug company, for $215 million.

January 2011 Buys BioVex, developer of an oncolytic vaccine, for up to $1 billion.

Source: Amgen

Amgen is paying $315 million for Kai Pharmaceuticals, a privately held biotech company developing peptide therapeutics. The deal adds to a string of purchases intended to bolster the big biotech firm’s pipeline and technology portfolio.

The centerpiece of the latest acquisition is KAI-4169, a therapeutic peptide for the treatment of hyperparathyroidism in people undergoing dialysis for chronic kidney disease. An intravenous version of KAI-4169, a calcium-sensing receptor agonist, is poised to enter Phase III trials, and Amgen will give Kai a loan before the deal closes to allow the clinical development to move forward. South San Francisco-based Kai is also developing the drug in a transdermal form, which is in earlier-stage trials.

Amgen has vast experience in the nephrology market. One of its top-selling drugs, Epogen, is used to treat anemia in people with chronic kidney disease.

Epogen sales have fluctuated in the past five years after high doses of the treatment were linked to serious side effects. Furthermore, Epogen is one of several Amgen products expected to encounter competition from biosimilars as early as 2015. Although a path to market for generic versions of biologics is still being worked out in the U.S., competitors are plowing ahead: In January, Hospira launched a Phase III trial of a biosimilar version of Epogen.

With biosimilars advancing, Amgen has been using a variety of strategies to bolster its pipeline and technology portfolio, expand its global presence, and do more with a smaller R&D budget. Earlier this month, for example, Amgen sold AstraZeneca a stake in the development of five clinical-stage monoclonal antibodies. That agreement, under which AstraZeneca paid Amgen $50 million up front and agreed to take on a healthy chunk of the costs to commercialize the drug candidates, allows the companies to share the risks of developing new drugs.

Analysts are reacting positively to Amgen’s recent spate of deals, all mid-sized mergers and acquisitions (M&A) ranging up to $1 billion in value. “We hope that Amgen will get more aggressive on M&A in the years ahead,” Citigroup biotech stock analyst Yaron B. Werber said in a note to investors earlier this year.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment